NCT04604327.

Study name	Ensayo clínico aleatorizado, abierto, para evaluar el efecto de dosis profilácticas o terapéuticas de bemiparina en pacientes con COVID‐19
Starting date	26 October 2020
Contact information	Ramon Lecumberri, MD, PhD Hospital Rey Juan Carlos Móstoles, Madrid, Spain +34 948296397 | rlecumber@unav.es
Methods	Open‐label, parallel‐assignment RCT
Participants	164 participants, ≥ 18 years, female and male Inclusion criteria: Age (≥ 18 years) Hospitalisation at conventional wards due to COVID‐19 related mild or moderate pneumonia (CURB65 < 3 points; Saturated O2 > 90%) 3‐4 points according to the WHO ordinal scale Confirmed COVID‐19 (PCR or other validated test) D‐dimer > 500 ng/mL Signed informed consent The patient is able, according to investigator's opinion, to deal with all the requirements of the clinical trial Exclusion criteria: nil
Interventions	Experimental: full therapeutic bemiparin (weight adjusted) Bemiparin at full therapeutic dose, adjusted to body weight, for 10 days Comparator: prophylactic bemiparin (3500 IU/day) Bemiparin 3500 IU daily for 10 days
Outcomes	Primary Clinical deterioration (time frame: 10 days) Combined outcome that includes number of patients who suffer any of the following: death, ICU admission, mechanical ventilatory support, progression to moderate or severe ARDS (according to Berlin criteria) or arterial or venous thrombosis
Notes	NCT04604327 | No data provided